169 related articles for article (PubMed ID: 36266539)
1. Results from a phase 1, randomized, double-blind, multiple ascending dose study characterizing the pharmacokinetics and demonstrating the safety and selectivity of the aldosterone synthase inhibitor baxdrostat in healthy volunteers.
Freeman MW; Bond M; Murphy B; Hui J; Isaacsohn J
Hypertens Res; 2023 Jan; 46(1):108-118. PubMed ID: 36266539
[TBL] [Abstract][Full Text] [Related]
2. Results From a Randomized, Open-Label, Crossover Study Evaluating the Effect of the Aldosterone Synthase Inhibitor Baxdrostat on the Pharmacokinetics of Metformin in Healthy Human Subjects.
Freeman MW; Bond M; Murphy B; Hui J; Isaacsohn J
Am J Cardiovasc Drugs; 2023 May; 23(3):277-286. PubMed ID: 36790596
[TBL] [Abstract][Full Text] [Related]
3. Phase 2 Trial of Baxdrostat for Treatment-Resistant Hypertension.
Freeman MW; Halvorsen YD; Marshall W; Pater M; Isaacsohn J; Pearce C; Murphy B; Alp N; Srivastava A; Bhatt DL; Brown MJ;
N Engl J Med; 2023 Feb; 388(5):395-405. PubMed ID: 36342143
[TBL] [Abstract][Full Text] [Related]
4. Results from a Phase 1 Study Assessing the Pharmacokinetics of the Aldosterone Synthase Inhibitor Baxdrostat in Participants with Varying Degrees of Renal Function.
Freeman MW; Halvorsen YD; Bond M; Murphy B; Isaacsohn J
Clin Pharmacol Drug Dev; 2024 Apr; 13(4):410-418. PubMed ID: 38311833
[TBL] [Abstract][Full Text] [Related]
5. LY3045697: Results from two randomized clinical trials of a novel inhibitor of aldosterone synthase.
Sloan-Lancaster J; Raddad E; Flynt A; Jin Y; Voelker J; Miller JW
J Renin Angiotensin Aldosterone Syst; 2017; 18(3):1470320317717883. PubMed ID: 28814143
[TBL] [Abstract][Full Text] [Related]
6. CYP11B2 inhibitor dexfadrostat phosphate suppresses the aldosterone-to-renin ratio, an indicator of sodium retention, in healthy volunteers.
Mulatero P; Groessl M; Vogt B; Schumacher C; Steele RE; Brooks A; Hossack S; Brunner HR
Br J Clin Pharmacol; 2023 Aug; 89(8):2483-2496. PubMed ID: 36914591
[TBL] [Abstract][Full Text] [Related]
7. Evaluating phase II results of Baxdrostat, an aldosterone synthase inhibitor for hypertension.
Awosika A; Cho Y; Bose U; Omole AE; Adabanya U
Expert Opin Investig Drugs; 2023; 32(11):985-995. PubMed ID: 37883217
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of aldosterone synthase: Does this offer advantages compared with the blockade of mineralocorticoid receptors?
Ando H
Hypertens Res; 2023 Apr; 46(4):1056-1057. PubMed ID: 36653520
[No Abstract] [Full Text] [Related]
9. Aldosterone synthase inhibition in humans.
Azizi M; Amar L; Menard J
Nephrol Dial Transplant; 2013 Jan; 28(1):36-43. PubMed ID: 23045428
[TBL] [Abstract][Full Text] [Related]
10. The selective aldosterone synthase inhibitor Baxdrostat significantly lowers blood pressure in patients with resistant hypertension.
Forzano I; Mone P; Varzideh F; Jankauskas SS; Kansakar U; De Luca A; Santulli G
Front Endocrinol (Lausanne); 2022; 13():1097968. PubMed ID: 36568122
[No Abstract] [Full Text] [Related]
11. Safety, Tolerability, and Pharmacokinetics of the Mineralocorticoid Receptor Modulator AZD9977 in Healthy Men: A Phase I Multiple Ascending Dose Study.
Whittaker A; Kragh ÅM; Hartleib-Geschwindner J; Albayaty M; Backlund A; Greasley PJ; Heijer M; Kjaer M; Forte P; Unwin R; Wernevik L; Ericsson H
Clin Transl Sci; 2020 Mar; 13(2):275-283. PubMed ID: 31584739
[TBL] [Abstract][Full Text] [Related]
12. Single- and multiple-dose escalation study to assess pharmacokinetics, pharmacodynamics and safety of oral esaxerenone in healthy Japanese subjects.
Kato M; Furuie H; Shimizu T; Miyazaki A; Kobayashi F; Ishizuka H
Br J Clin Pharmacol; 2018 Aug; 84(8):1821-1829. PubMed ID: 29688582
[TBL] [Abstract][Full Text] [Related]
13. Baxdrostat: A Novel Aldosterone Synthase Inhibitor for Treatment Resistant Hypertension.
Dogra S; Shah S; Gitzel L; Pusukur B; Sood A; Vyas AV; Gupta R
Curr Probl Cardiol; 2023 Nov; 48(11):101918. PubMed ID: 37399857
[TBL] [Abstract][Full Text] [Related]
14. Safety, Tolerability and Pharmacokinetics of Icapamespib, a Selective Epichaperome Inhibitor, in Healthy Adults.
Silverman MH; Duggan S; Bardelli G; Sadler B; Key C; Medlock M; Reynolds L; Wallner B
J Prev Alzheimers Dis; 2022; 9(4):635-645. PubMed ID: 36281667
[TBL] [Abstract][Full Text] [Related]
15. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
[TBL] [Abstract][Full Text] [Related]
16. Safety, tolerability and pharmacokinetics of dalcetrapib following single and multiple ascending doses in healthy subjects: a randomized, double-blind, placebo-controlled, phase I study.
Derks M; Anzures-Cabrera J; Turnbull L; Phelan M
Clin Drug Investig; 2011; 31(5):325-35. PubMed ID: 21366361
[TBL] [Abstract][Full Text] [Related]
17. Multiple-dose pharmacokinetics and safety of bevirimat, a novel inhibitor of HIV maturation, in healthy volunteers.
Martin DE; Blum R; Doto J; Galbraith H; Ballow C
Clin Pharmacokinet; 2007; 46(7):589-98. PubMed ID: 17596104
[TBL] [Abstract][Full Text] [Related]
18. The randomized, single- and multiple- ascending dose studies of the safety, tolerability, pharmacokinetics of CSPCHA115 in healthy Chinese subjects.
Jing S; Liu W; Yang K; Lin Y; Yao X; Sun G
Clin Transl Sci; 2023 Mar; 16(3):447-458. PubMed ID: 36495036
[TBL] [Abstract][Full Text] [Related]
19. Multiple-Ascending Dose Study in Healthy Subjects to Assess the Pharmacokinetics, Tolerability, and CYP3A4 Interaction Potential of the T-Type Calcium Channel Blocker ACT-709478, A Potential New Antiepileptic Drug.
Richard M; Kaufmann P; Ort M; Kornberger R; Dingemanse J
CNS Drugs; 2020 Mar; 34(3):311-323. PubMed ID: 31994022
[TBL] [Abstract][Full Text] [Related]
20. Safety and pharmacokinetics of NXN-188 after single and multiple doses in five phase I, randomized, double-blind, parallel studies in healthy adult volunteers.
Vaughan D; Speed J; Medve R; Andrews JS
Clin Ther; 2010 Jan; 32(1):146-60. PubMed ID: 20171420
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
